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Metallo-β-lactamases (MBLs) hydrolyze almost all β-lactam antibi-
otics and are unaffected by clinically available β-lactamase inhibi-
tors (βLIs). Active-site architecture divides MBLs into three classes
(B1, B2, and B3), complicating development of βLIs effective against
all enzymes. Bisthiazolidines (BTZs) are carboxylate-containing, bicy-
clic compounds, considered as penicillin analogs with an additional
free thiol. Here, we show both L- and D-BTZ enantiomers are micro-
molar competitive βLIs of all MBL classes in vitro, with Kis of 6–15 μM
or 36–84 μM for subclass B1 MBLs (IMP-1 and BcII, respectively), and
10–12 μM for the B3 enzyme L1. Against the B2 MBL Sfh-I, the L-BTZ
enantiomers exhibit 100-fold lower Kis (0.26–0.36 μM) than D-BTZs
(26–29 μM). Importantly, cell-based time-kill assays show BTZs re-
store β-lactam susceptibility of Escherichia coli-producing MBLs
(IMP-1, Sfh-1, BcII, and GOB-18) and, significantly, an extensively
drug-resistant Stenotrophomonas maltophilia clinical isolate express-
ing L1. BTZs therefore inhibit the full range of MBLs and potentiate
β-lactam activity against producer pathogens. X-ray crystal structures
reveal insights into diverse BTZ binding modes, varying with orien-
tation of the carboxylate and thiol moieties. BTZs bind the di-zinc
centers of B1 (IMP-1; BcII) and B3 (L1) MBLs via the free thiol, but
orient differently depending upon stereochemistry. In contrast, the
L-BTZ carboxylate dominates interactions with the monozinc B2 MBL
Sfh-I, with the thiol uninvolved. D-BTZ complexes most closely resem-
ble β-lactam binding to B1 MBLs, but feature an unprecedented dis-
ruption of the D120–zinc interaction. Cross-class MBL inhibition
therefore arises from the unexpected versatility of BTZ binding.
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The production of metallo-β-lactamases (MBLs) by Gram-neg-ative pathogens, such as Escherichia coli, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Steno-
trophomonas maltophilia, is a major contributor to bacterial anti-
biotic resistance (1, 2). MBLs are able to hydrolyze most β-lactam
antibiotics, including clinically important serine β-lactamase in-
hibitors (βLIs, clavulanic acid and penicillanic acid sulfones) and
the carbapenems, which are often used as a “last-resort” therapy
for serious infections (3–6). MBLs can be divided into three sub-
classes—B1, B2, and B3—based on sequence, structure, and zinc
ion utilization (2, 7–9). All three classes contain a similar overall
αββα-fold, with the active site lying in a groove between the two
β-sheets (Fig. 1). In most di-zinc B1 enzymes, such as IMP-1 (10),
BcII (11), and NDM-1 (12), the Zn1 site is tetrahedrally co-
ordinated by a water molecule (Wat1), H116, H118, and H196
[standard MBL numbering scheme (7) used throughout], whereas
Zn2 is bound by Wat1, a second water molecule (Wat2), D120,
C221, and H263 in a trigonal bipyrimidal coordination. A water
molecule (Wat1) bridges/coordinates Zn1 and Zn2 in an arrange-
ment that is suited to activate it as a nucleophile.
In monozinc B2 enzymes, such as CphA (13) and Sfh-I (14),
binding of the zinc ion is representative of the Zn2 site in B1 en-
zymes, with coordination by a water molecule (Wat1), D120, C221,
and H263, in a tetrahedral rather than trigonal bipyrimidal geom-
etry. Two water molecules (Wat1 and Wat2) are present in the
active site, with Wat2 hydrogen-bonded to H118 and H196, and
Wat1 coordinating Zn2, lying approximately equidistant between
Zn2 (2.3 Å) and Wat2 (2.6 Å). Wat2 is believed to be activated by
H118, rather than a zinc ion, to act as the nucleophile during an-
tibiotic hydrolysis (14).
Di-zinc B3 enzymes [e.g., L1 (15) and AIM-1 (16)] have similar
active-site architectures to B1 MBLs, with Zn1 in tetrahedral
coordination with a water molecule (Wat1), H116, H118, and
H196; and the nucleophilic water (Wat1) bridging Zn1 (1.9 Å)
and Zn2 (2.1 Å). Zn2, however, is coordinated by D120, H121,
H263, and an additional water molecule (Wat2) in a distorted
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trigonal bipyramidal geometry. To date, clinically useful βLIs of
any of the three MBL classes have not been identified, and the
aforementioned structural differences have complicated develop-
ment of βLIs with cross-class (B1, B2, and B3) activity.
In response to this urgent medical need, we have developed
and synthesized four bisthiazolidine (BTZ) compounds, L-CS319
(1a), D-CS319 (1b), L-VC26 (2a), and D-VC26 (2b) (blue, gray,
orange, and cyan, respectively, in Fig. 2) (17, 18). These βLIs
contain both a free thiol, which is a high-affinity zinc-binding
group, and two defining properties of β-lactam substrates, a
feature hitherto overlooked in MBL inhibitor design. These are,
first, a carboxylate moiety that in penicillins and carbapenems is
able to bind Zn2 and interact with conserved residues on the
protein main chain (19, 20); and, second, a tetrahedral bridge-
head nitrogen that interacts with Zn2 as hydrolysis of bicyclic
β-lactam antibiotics proceeds (21, 22). The absence of structural
information on how a single compound can bind and inhibit all
three classes of MBLs hinders further development of any potent
cross-class inhibitors. We therefore characterized cross-class
MBL inhibition in vitro, and in MBL-producing bacteria, by the
four previously synthesized BTZs, and obtained crystal structures
for B1 (IMP-1 and BcII), B2 (Sfh-I), and B3 (L1) MBLs com-
plexed with the novel scaffold, including one compound (1a) now
structurally characterized in all three classes. These data dem-
onstrate how a single compound class can use multiple modes of
binding to inhibit, in vitro and in producer organisms, MBLs of
different classes and active-site architectures, and identify routes
to further improve potency against the range of target enzymes.
Results
BTZs Are Cross-Class MBL Inhibitors in Vitro. Previous kinetic char-
acterization of BTZ inhibition of selected MBL targets dem-
onstrated them to be micromolar competitive inhibitors of
carbapenem (imipenem) or cephalosporin (nitrocefin) hydrolysis
by the B1 MBLs, VIM-2 and NDM-1, with Kis varying between
3.7 ± 0.3 and 19 ± 3 μM (17, 18) (Table 1). Here, we evaluate
their cross-class inhibition potential by measuring the in vitro
effect of BTZs on imipenem hydrolysis by VIM-2 and other
MBLs of subclasses B1 [Bacillus cereus BcII (11, 23, 24) and
Serratia marsescens IMP-1 (10)], B2 [Serratia fonticola Sfh-I (14,
25)], and B3 [S. maltophilia L1 (15, 26)]. To ensure coverage of
diverse MBLs, we also assayed activity against the structurally
uncharacterized, atypical Elizabethkingia meningoseptica GOB-
18, reconstituted in its fully active monozinc form (27).
These data reveal the compounds to be competitive, micro-
molar inhibitors of all MBL classes (Figs. S1 and S2), with Kis
between 0.26 ± 0.03 μM and 84 ± 6 μM (Table 1). The inhibition
of B1 MBLs is little affected by the stereochemistry on the BTZs
[D- (1b, 2b) or L- (1a, 2a) BTZs], or by the presence of a gem-
dimethyl group (2a, 2b), with Ki values varying by 2- and 2.5-fold
(IMP-1 and BcII, respectively). In particular, BTZ potency
against IMP-1 or VIM-2 is the same for both enantiomers,
whereas the addition of a gem-dimethyl group (2a/2b) resulted in
a two- to threefold increase in Ki. In contrast, against BcII,
D-BTZs were 1.5- to 2.5-fold less potent than the L-BTZs, whereas
the gem-dimethyl group had little effect on potency (2a/2b Ki is
up to 1.5-fold greater than 1a/1b). Against the B3 MBL L1, all
compounds exhibit near identical Ki values, between 10 and
12 μM ± 1–2, whereas only 2b exhibits similar potency against the
B3 MBL GOB-18 (10 μM), with the three other BTZs three-
to fourfold less potent (30–41 μM ± 1–4). The unusual GOB-18
active site, in which the Zn1 ligand H116 is replaced by Q and
only the Zn2 site is occupied in vitro (27), likely accounts for
these small differences we observe in potency against B3 en-
zymes. Although it is possible periplasmic GOB-18 is di-zinc, as
GOB-1 (28), importantly these data show the BTZ scaffold in-
hibits MBLs with even highly atypical active-site architectures.
Only against B2 Sfh-I is there strong stereochemical preference,
with L-BTZs (1a, 2a) greater than 100-fold more potent than their
corresponding D-enantiomers (1b, 2b). As is the case for the B1 and
B3 enzymes, there is little change in BTZ potency on addition of a
gem-dimethyl group, with 1a and 2a exhibiting similar, submicromolar
Ki values (0.26 ± 0.03 μM and 0.36 ± 0.04 μM, respectively).
BTZs Restore β-Lactam Efficacy Toward MBL-Producing Isolates. To
assess the clinical potential of BTZs, time-kill assays were performed
using E. coli cells expressing the B1MBLs IMP-1 and BcII, B2 Sfh-I,
Fig. 1. Architecture of B1, B2, and B3 metallo-β-lactamases. The common
αββα-fold of representative MBLs is colored from the N (light blue) to C
terminus (light red), and is shown alongside a close up view of the active-site
(boxed). Zinc ions (gray) and water molecules (red) are represented as
spheres. Zinc coordination bonds are shown as gray dashes, with the cor-
responding residues (labeled) shown as sticks. (A) B1 BcII (PDB ID code 4C09),
(B) B2 Sfh-I (PDB ID code 3SD9), and (C) B3 L1 (PDB ID code 1SML).
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Fig. 2. Chemical structures of bisthiazolidine inhibitors. Bisthiazolidines 1a
(L-CS319, blue), 1b (D-CS319, gray), 2a (L-VC26, orange), and 2b (D-VC26, cyan).
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and the B3 enzyme GOB-18 (Fig. S3). Additionally, a multidrug-
resistant S. maltophilia clinical isolate producing both the B3 MBL
L1 and the serine β-lactamase L2 was also studied (Fig. 3 and Fig.
S4). The βLIs do not have any antimicrobial effect on their own, as
differences could not be detected in viable cell number between cells
exposed to BTZs and broth-only controls. Viable cell counts fol-
lowing exposure to sublethal concentrations of β-lactams (imipenem
and ticarcillin-clavulanate for the E. coli and S. maltophilia isolates,
respectively) in the presence of BTZs demonstrated that BTZs are
able to inactivate the MBLs in clinically relevant strains, as evi-
denced by the significant reductions in bacterial count (>103). Po-
tentiation of antibiotic activity against S. maltophilia is particularly
significant because strains of this Gram-negative pathogen tend to
be extensively multidrug-resistant, particularly because of the ex-
pression of two distinct β-lactamases and several membrane-
spanning multidrug efflux pumps (29).
Structure Determination of BTZ Complexes with B1, B2, and B3 MBLs.
An understanding of how BTZs inhibit all three classes of MBL
requires structural information for representative BTZ:MBL
complexes to complement our previously obtained structures of
1a bound to the B1 MBLs VIM-2 and NDM-1 (17, 18). We
therefore crystallized the MBLs IMP-1 and BcII (subclass B1),
Sfh-I (B2), and L1 (B3) and soaked the crystals in the four BTZs.
Cocomplex structures were solved for IMP-1 with 1b (2.30 Å
resolution) and 2a (2.30 Å); BcII with 1b (1.80 Å); Sfh-I with 1a
(1.30 Å); and L1 with 1a (1.63 Å), 1b (1.84 Å), and 2b (1.80 Å)
(Table S1). For B2 Sfh-I we were unable to obtain a cocomplex
with both BTZ stereoisomers, consistent with the in vitro ob-
servation that D-BTZs were at least 100-fold less-potent Sfh-I
inhibitors than L-BTZs. In all seven cases there was clear Fo–Fc
density in the MBL active site into which the corresponding li-
gand could be modeled (Fig. S5). Further ligand validation sta-
tistics (real-space R value, local ligand density fit, and real-space
correlation coefficient) are presented in Table S2.
IMP-1 crystallized in the space group P212121, with four
molecules in the asymmetric unit (ASU), not previously de-
scribed. Electron density consistent with bound 2a was observed
in three of the four subunits (average B-factor 1.8 times greater
than the protein main chain), whereas 1b could be confidently
modeled in all four molecules of the ASU (B-factors 1.1 times
greater than the main chain). For comparison, we have also
solved, to 1.98 Å resolution, the structure of uncomplexed di-
zinc IMP-1, also in the space group P212121 (SI Results). BcII
crystallized in the previously described space group C2 (30), with
one molecule in the ASU and one molecule of 1b identified in
the active site (B-factor 1.6 times greater than the main chain).
Sfh-I crystallized in space group P21 (14), with 1a clearly defined
in both monomers of the ASU (B-factors 1.2 times greater than
the protein main chain). L1 crystallized in space group P6422
(15), with one molecule in the ASU, into which 1a, 1b, and 2b
were modeled into clearly defined density (B-factors 2.1, 1.8, and
1.7 above the main chain). Ligands were refined at full occu-
pancy for all but L1:1b (ligand occupancy 0.76) and L1:2b (0.81).
A Dual-Mode of Binding for L-BTZs to MBLs. The IMP-1:2a (Fig. 4A)
and L1:1a (Fig. 4B) structures reveal similar binding modes for
L-BTZs to IMP-1 (B1) and L1 (B3) (Fig. 4C). These modes also
resemble the previously observed binding mode of 1a to both
VIM-2 (18) and NDM-1 (17) (Fig. S6). In all these structures,
the thiol of the BTZ mercaptomethyl group is positioned nearly
equidistant between the two zinc ions (between 2.22 and 2.43 Å ±
0.14 and 0.23 Å) (see Table S1 for coordinate errors and Table S3
for detailed distances). BTZ binding displaces the zinc-bridging
nucleophilic water/hydroxide (Wat1) that is observed in the native
MBL active site (Fig. S7), with a concomitant small increase in the
Zn1–Zn2 distance of approximately 0.3/0.4 Å (±0.14/0.23 Å),
compared with uncomplexed enzymes (Table S3). L-BTZ binding
is further stabilized by direct interaction of its carboxylate with
structurally equivalent side chains that are implicated in substrate
binding (19, 20, 31), K224 in IMP-1 and S223 in L1. 1a also makes
hydrophobic interactions with two residues on L1 (W38 and P226),
and 2a contacts two (W64 and V67) on the flexible L3 loop (32)
positioned above the IMP-1 active site (gray side chains in Fig. 4 A
and B). Despite these similarities, BTZ binding results in a larger
ligand:protein buried surface area in the IMP-1:2a (330 Å2) com-
plex compared with L1:1a (264 Å2), largely because of the L3 loop
which is present in IMP-1 but not L1 (Fig. 4).
In contrast, L-BTZ binding to the monozinc B2 MBL Sfh-I
differs substantially from that to B1 or B3 enzymes. In the
complex with 1a, the 1a-carboxylate group interacts with the
active-site zinc (1.84 ± 0.03 Å), and is within hydrogen-bonding
distance of two protein side chains, N233 (2.97 ± 0.03 Å) and
H196 (2.96 ± 0.03 Å) (Fig. 5A). Binding to Sfh-I results in ap-
proximately 265 Å2 of buried surface area, and is stabilized by
interactions with four hydrophobic residues (W87, F156, I153,
F236) (Fig. 5A, gray). In addition, although BTZ binding has
little effect on the overall Sfh-I structure [rmsd 0.33 Å over 228
Cα atoms, compared with native Sfh-I (14)], there are significant
Table 1. In vitro competitive inhibition of MBLs by bisthiazolidines
Inhibition constants (Ki/μM)
MBL subclass Enzyme Substrate 1a 1b 2a 2b Source
B1 NDM-1 Imipenem 7 ± 1 19 ± 3 18 ± 3 12 ± 1 (17)
VIM-2 Imipenem 2.9 ± 0.4 3.2 ± 0.4 6 ± 1 10 ± 2 —
IMP-1 Imipenem 8 ± 2 6 ± 1 15 ± 3 14 ± 3 —
BcII Imipenem 36 ± 2 53 ± 5 32 ± 3 84 ± 6 —
B2 Sfh-I Imipenem 0.26 ± 0.03 26 ± 3 0.36 ± 0.04 29 ± 3 —
B3 L1 Imipenem 12 ± 1 10 ± 1 11 ± 2 10 ± 1 —
GOB-18 Imipenem 41 ± 4 30 ± 2 31 ± 2 10 ± 1 —
Fig. 3. Bisthiazolidines restore the in vitro activity of ticarcillin-clavulanate
against a S. maltophilia clinical isolate. Bacteria were grown at sublethal con-
centrations of a mixture of ticarcillin (TIC, 64 μg/mL) and clavulanate (CLV, 2 μg/
mL), or in combination with 100 μg/mL of each compound. Viable cells were
recovered at 4, 8, and 12 h. Results shown are the mean of three biological
replicates ± SD.
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rearrangements within the active site (Fig. 5B). The BTZ carboxylate
displaces the water zinc ligand (Wat1), maintaining the tetrahedral
zinc geometry, and causing a flip and approximately 0.6 Å (± 0.03 Å)
movement of the H196 side chain. This movement results in a loss of
interaction of H196-Ne2 with the nucleophilic water (Wat2), which
moves 0.9 Å deeper into the active site and closer to Zn2 (3.0 Å
compared with 3.5 Å in uncomplexed Sfh-I, ± 0.03 Å). Notably, and
in direct contrast to the structures obtained for complexes with IMP-1
and L1, the BTZ thiol is not involved in interactions with the Sfh-I
zinc site.
A Distinct Mode of D-BTZ Binding to L1. We next investigated
binding of D-BTZ inhibitors to our chosen MBL targets. Sur-
prisingly, structural analysis of D-BTZs bound to the B3 en-
zyme L1 revealed a third mode of binding. Similar to the L1:1a
complex, the 1b-mercaptomethyl group dominates L1 active-
site interactions, with the thiol bridging the two zinc ions, again
resulting in a small (0.4 ± 0.17 Å) increase in the Zn1–Zn2
distance (Table S3). However, the carboxylate group is no
longer bound to S223, but instead interacts, via a water mol-
ecule, with Y32 on the nonconserved N-terminal extension of
L1 (2.74 Å BTZ–water, 2.40 Å water–Y32, ± 0.17 Å) (Fig. 6A).
This interaction causes an approximate 90° rotation of D-BTZ
around the thiol compared with L-BTZ, orientating the BTZ to
make hydrophobic interactions with three residues (P226, F156,
I162) (Fig. 6B) of which only P226 is involved in binding 1a.
Despite this, the buried surface area on ligand binding is similar in
both the L1:1a and L1:1b complexes (264 Å2 and 268 Å2, re-
spectively). The structure of L1:2b indicates that the presence of a
dimethyl group does not affect this mode of binding, although
unsurprisingly there is a slight increase in the buried surface area
(279 Å2). 2b makes the same hydrophobic interactions as 1b (Fig.
6C) and is bound with similar thiol–zinc and Zn1–Zn2 distances
(Table S3). As in the L1:1b structure, interaction of the 2b car-
boxylate with Y32 is also mediated by a water molecule (2.81 Å
2b–water, 2.53 Å water–Y32, ± 0.18 Å).
Binding of 1b to B1 MBLs Involves Multiple Ligand–Zinc Interactions.
Structures of 1b bound to the B1 enzymes BcII and IMP-1 reveal
multiple interactions of the inhibitor with both zinc ions in the
active site (Fig. 7). However, BTZ binding does not result in global
conformational changes for either IMP-1 (IMP:1b compared with
Fig. 4. L-bisthiazolidine binding to B1 (IMP-1) and B3 (L1) metallo-β-lactamases. Close-up view of IMP-1 and L1 active sites with bound L-BTZ (sticks, colored as
in Fig. 2). Protein main chain is colored from the N (light blue) to C terminus (light red). Residues that interact with the zinc ions (Zn1 and Zn2, gray spheres)
are shown as sticks (colored as main chain), whereas hydrophobic residues that stabilize BTZ binding are shown as gray sticks. IMP-1 K224 and L1 S223
(labeled) interact with the BTZ carboxylate. (A) 2a bound to B1 IMP-1. Protein–zinc interactions are shown as gray dashes and BTZ–protein or BTZ–zinc in-
teractions are shown as yellow dashes. (B) 1a bound to B3 L1. Interactions shown as in A. (C) Superposition of IMP-1:2a (orange) and L1:1a (blue). BTZ–protein
or BTZ–zinc interactions are shown as dashes colored orange (IMP-1:2a) or blue (L1:1a).
Fig. 5. 1a binding to Sfh-I and concomitant active-
site conformational changes. Active-site zinc ions
(gray spheres) and water molecules (red spheres) are
labeled. (A) 1a (blue) bound in the active site of B2
Sfh-I (main chain colored as in Fig. 1). Hydrophobic
residues, on the α3 region and within the active site,
involved in binding 1a are shown as gray sticks. The
1a carboxylate bridges N233 and H196 (sticks). Resi-
dues involved in binding the active-site zinc ion (Zn2,
gray sphere) and water (Wat2, red sphere) are rep-
resented as sticks. Interactions of 1a with the protein
main chain or Zn2 are shown as yellow dashes. Pro-
tein–zinc and protein–water interactions are shown
as gray dashes. (B) Superposition of Sfh-I:1a (blue)
with unliganded, native Sfh-I (PDB ID code 3SD9,
green). Interactions of H118 and H196 with the BTZ
or Wat2 are shown as dashes.
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uncomplexed IMP-1, rmsd = 0.28 Å over 222 Cα atoms) or BcII
(BcII:1b compared with uncomplexed BcII, rmsd = 0.41 Å over
223 Cα atoms). 1b binding to IMP-1 (buried surface area 292 Å2)
features four ligand–zinc interactions (Fig. 7A), the carboxylate
(2.1 ± 0.26 Å) and bridging nitrogen (2.8 ± 0.26 Å) with Zn2, and
the thiol bridging Zn1 (2.0 ± 0.26 Å) and Zn2 (2.2 ± 0.26 Å), with
the Zn1–Zn2 distance increasing by 0.2–0.3 Å (± 0.26 Å). Binding
is further favored by interaction of the carboxylate with Lys224, as
is the case with 2a binding to IMP-1.
As in the IMP-1:2a complex, residues W64 and V67 in the L3
loop are involved in hydrophobic interactions with the inhibitor,
with W64 in particular forming π-stacking interactions with the
BTZ bicyclic ring. Despite previous observations that the NDM-1
L3 loop may “close” on 1a binding (17), the position of the IMP-1
L3 loop is more stable, with no substantial conformational
shifts evident on BTZ binding compared with the native struc-
ture. 1b makes very similar interactions (Fig. 7B) on binding BcII
(buried surface area 287 Å2): that is, the carboxylate (2.0 ± 0.13 Å)
and bridging nitrogen (2.7 ± 0.13 Å) with Zn2, the carboxylate
with K224 (2.9 ± 0.13 Å), and the thiol equidistant between
active-site zincs (2.2 ± 0.13 Å), with the Zn1–Zn2 distance in-
creasing by 0.3 ± 0.13 Å compared with uncomplexed BcII (PDB
ID code 4C09). Three hydrophobic interactions are formed, one
with W87 and two with residues F61 and V67 in the L3 loop, which
form after the L3 loop closes by ∼3.0–4.6 ± 0.13 Å compared with
its position in the native structure (Fig. S8). As observed in the 1a:
Sfh-I complex, there are also important rearrangements within the
IMP-1 and BcII active sites on 1b binding (Fig. 7 C and D). Re-
markably, the electron density clearly defines a displacement of the
Zn2 ligand D120 and consequent loss of the D120–Zn2 coordination
interaction (Fig. S9). Instead, D120 reorients to form hydrogen
bonds with either E59 (IMP-1) or S69 (BcII), which results in an
irregular five-coordinate geometry for Zn2 and a 1.0± 0.26 Å (IMP-1)
or 0.7 ± 0.13 Å (BcII) movement of Zn2 away from D120.
Discussion
Here we show the structural basis for micromolar competitive
inhibition of all three MBL classes by BTZs, including of clini-
cally relevant enzymes from opportunist bacterial pathogens,
such as E. coli, P. aeruginosa, or S. maltophilia, which can cause
severe or even life-threatening infections. BTZs are able to cross
the outer membrane of Gram-negative bacteria and enter the
periplasm, inhibiting MBL activity in vivo and potentiating the ac-
tivity of carbapenems and other β-lactams against MBL-producing
clinical isolates. Our data demonstrate this simple scaffold,
which in several aspects resembles the architecture of the bicyclic
β-lactam substrate, is able to overcome the variations in MBL
active-site architecture across subclasses to achieve roughly
equipotent inhibition of all MBLs tested. Such variations, which
encompass differences in zinc ligands, interaction partners for
the carboxylate group at C2/C3 of β-lactams and the positions
and locations of hydrophobic surfaces and conformationally
flexible surface loops adjacent to the active site, have manifest as
substantial differences in potency against different MBL targets
for some other inhibitor classes. Unexpectedly our structural
data reveal that BTZ inhibition of different MBLs is unique and
characterized by multiple binding modes that vary both with
target enzyme and with the BTZ enantiomer used.
The crystal structures of MBL:BTZ complexes presented here
and in previous publications (17, 18) identify that BTZs use four
distinct modes of binding to the range of MBL targets. L-BTZs
adopt similar binding modes to the B1 and B3 binuclear en-
zymes, with overall BTZ orientation retained across enzymes
that use different side chains [K224 (BcII, IMP-1, NDM-1);
R228 (VIM-2) and S223 (L1)] in interactions with the BTZ
carboxylate group that may or may not involve the intermediacy
of bound water molecules. This binding mode is also robust to
differences in the composition (particularly with respect to the
positions of aromatic residues) and orientation of the mobile L3
loop that is a feature of most B1 MBLs, but absent in B3 en-
zymes such as L1.
In contrast, D-BTZ binding differs profoundly between com-
plex structures for B1 (BcII, IMP-1) and B3 (L1) enzymes, with
interactions involving the carboxylate group (with Zn2 and the
K224 side chain) a feature of the BcII and IMP-1 complexes but
absent from those with L1. The differing L1 active-site archi-
tecture, which compared with B1 MBLs lacks an extended L3
loop and instead features elongated linkers between other sec-
ondary structural elements adjacent to the active site and hy-
drophobic residues at different positions, likely imposes a
different orientation upon the bound D-BTZ ligand. The fourth
binding mode is observed in B2 MBL Sfh-I complexed with 1a.
In B2 enzymes conserved hydrophobic residues on the long α3 helix
adjacent to the active site form a “hydrophobic wall” proposed
Fig. 6. 1b binding to B3 MBL L1. A water molecule (red sphere) mediates the interaction of Y32 (sticks, labeled) with the D-BTZ carboxylate, but S223 (sticks,
labeled), which binds 1a, is not involved. Hydrophobic and zinc-binding residues represented as Fig. 4. (A) 1b (gray) bound in the active site of B3 L1 (colored
as in Fig. 4). Interactions shown as in Fig. 4. (B) Superposition of L1:1b (gray) with L1:1a (blue). Interactions between the BTZ and protein are shown as gray or
blue dashes, according to their respective structures. (C) 2b (cyan) bound to B3 L1, represented as in B.
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to contribute to selective carbapenem binding (33, 34). In the
Sfh-I:1a structure, the BTZ thiol was observed buried deep into
the hydrophobic cavity formed by residues W87, I153, F236,
and F156, rather than, as anticipated, involved in interactions with
the zinc center. We consider it likely that positioning of the thiol
moiety in this cavity by the unique hydrophobic wall of B2 MBLs
also explains the high selectivity of Sfh-I for L- over D-BTZs, which
is not observed in the B1 and B3 family members studied in this
work. In addition, the carboxylate of bound D-BTZ would be
positioned differently at the Zn site, requiring different ancillary
interactions with the protein main chain. In Sfh-I, unlike our ob-
servations of BTZ binding to L1 and IMP-1, the more constrained
active site provides little room for a second BTZ binding mode. It
is likely that significant conformational changes within the active
site would be required to bind D-BTZs, resulting in higher Kis in
vitro, whereas in the crystalline state these are prevented by
packing interactions. Taken together, these data clearly indicate
that the variation in active-site architecture between different
MBLs is such that the ability to support more than one mode of
binding may be necessary to achieve activity toward the full range
of targets for even simple inhibitor scaffolds.
Investigation of the activity of BTZs as potential MBL inhib-
itors was in part prompted by their structural similarities to
β-lactam substrates. Comparison of L-BTZ:MBL and hydrolyzed
substrate:MBL structures highlights both differences and simi-
larities in the modes of ligand binding (Fig. 8). B1 and B3 MBLs
bind antibiotic similarly, exemplified by the NDM-1:ampicillin
(19) (Fig. 8A, green) and L1:moxalactam (20) (Fig. 8B, green)
structures, respectively. In particular, in binuclear MBLs K224
(B1) or S223 (B3) interact with the carboxylate at C2/C3 of the
hydrolyzed β-lactam. However, in both cases β-lactam binding is
also characterized by interactions of Zn2 with the β-lactam ni-
trogen and carboxylate, whereas equivalent interactions are
not observed in the 1a:MBL complexes. The absence of an in-
teraction between the BTZ nitrogen (a component of the bicyclic
ring structure) and Zn2 is, however, consistent with several
models of MBL-catalyzed antibiotic hydrolysis that feature Zn2-
coordination by the β-lactam nitrogen only after the amide bond
has been cleaved and the β-lactam ring opened (21, 22). On the
other hand, BTZ binding involves the thiol group bridging Zn1
and Zn2, and displacement of the nucleophilic water (Wat1),
whereas in complexes with hydrolyzed antibiotics Wat1 is present
(19, 20), albeit with differences in zinc geometry. These differ-
ences are particularly evident in the NDM-1:ampicillin structure
[PDB ID code 3Q6X (19)] where Wat1 is more tightly bound to
a trigonal byprimidal Zn1 (2.1 Å) than Zn2 (2.7 A). In com-
parison, in the native NDM-1 structure [PDB ID code 3SPU
(12)], Wat1 is more consistently (between the five chains in the
ASU) equidistant between Zn1 (tetrahedral geometry) and Zn2.
1b binding to L1 also involves fewer interactions with Zn2 than
Fig. 7. 1b binding to B1 MBLs BcII and IMP-1. 1b
bound in the active of B1 MBLs (A) IMP-1 and (B) BcII
(colors and interactions as in Fig. 4). In both A and B,
K224 binds the 1b carboxylate and the D120–Zn2 co-
ordination is disrupted. (C) Superposition of IMP-1:1b
(gray; zinc ions, light gray) with unliganded, native
IMP-1 (green; zinc ions, dark gray). Binding causes
movement of Zn2, and loss of the D120–Zn2 in-
teraction. (D) Superposition of BcII:1b (gray; zinc ions,
light gray) with unliganded, native BcII (PDB ID code
4C09 green; zinc ions, dark gray). Binding is similar to C,
causing the same rearrangements within the active site.
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hydrolyzed antibiotic (Fig. 8C), although it is notable that Y32,
which helps to stabilize inhibitor binding by interaction with the
BTZ carboxylate, also stabilizes antibiotic binding through in-
teraction with the moxalactam carbonyl oxygen (20).
In comparison with MBL:L-BTZ complexes, (or binding of
D-BTZs to L1), 1b binding to the B1 MBLs IMP-1 and BcII more
closely represents that of hydrolyzed β-lactams. This is most
evident with respect to interactions involving Zn2 and Lys224, as
highlighted by comparison of IMP-1:1b and BcII:1b complexes
with that of hydrolyzed ampicillin bound to NDM-1 (19) (Fig. 9
A and B, respectively). In particular, both the BTZ and am-
picillin carboxylate groups interact with Zn2 (2.0–2.2 Å) and
hydrogen bond to Lys224 Ne (2.5–2.9Å). Furthermore, the
bridgehead nitrogen of D-BTZs lies within coordination distance
of Zn2 (2.7–2.8 ± 0.13/0.26 Å), although this interaction is not as
strong as the equivalent in the NDM-1:ampicillin complex in-
volving the β-lactam nitrogen (2.2 Å) (Fig. 9 C–E). However,
despite the closer resemblance of their binding to that of anti-
biotic substrates, comparison of Ki values shows D-BTZs to be no
more effective B1 MBL inhibitors than the L-BTZs that exhibit
different binding modes (Table 1). This difference may arise
from D-BTZ binding causing the energetically unfavorable dis-
ruption of the D120–Zn2 interaction. This D120 rearrangement
may be necessary to relieve conformational strain about the Zn2
site arising from interaction with bound D-BTZ, or may be a
means of relieving steric clashes because of the orientation of
D-BTZ in the active site imposed by interactions involving the
carboxylate group and, in particular, positioning of the sulfur
atom as a bridging ligand to both zinc ions.
Similar to B1 and B3 enzymes, structural characterization of
hydrolyzed biapenem binding to the B2 MBL CphA (34) (Fig.
8D, green) reveals the antibiotic to interact with Zn2 via its
β-lactam nitrogen atom and carboxylate group, and by hydrogen
bonds to Lys224, Thr157, and T119. In comparison, in Sfh-I:1a,
the BTZ carboxylate group, and not the nitrogen atom, interacts
with the Sfh-I zinc ion, as well as two residues that are not in-
volved in antibiotic binding to CphA, H196, and N233 (Fig. 8D,
blue). Binding of hydrolyzed biapenem also involves residues
W87, I153, F236, and F156 of the hydrophobic wall, a unique
structural feature of B2 MBLs. These residues also stabilize
binding of 1a, specifically the thiol moiety, indicating that the
hydrophobic wall is also important in BTZ binding by B2 MBLs
(34). However, although thiol compounds have been shown as
high-affinity MBL ligands (35), giving rise to the identification of
a variety of thiol-based inhibitors, the absence of thiol:Zn2 in-
teractions in our Sfh-I:BTZ crystal structure supports consider-
ation of other metal binding groups, such as carboxylates or
phosphonates, in searches for broad-spectrum MBL inhibitors.
Numerous chemical scaffolds have been explored as candidate
MBL inhibitors, in a search that is given added impetus by the
increasing dissemination of MBLs on mobile genetic elements
and in clinically significant pathogens. However, studies to date
have focused upon relatively restricted numbers of target en-
zymes, and characterization, particularly at structural level, has
not in most cases extended to all three enzyme subclasses. Cap-
topril (an angiotensin-converting enzyme andMBL inhibitor) is the
most studied MBL inhibitor, with complexes of one or both of its
enantiomers described for B1 (BcII [PDB ID codes 4C1H (36) and
4C1C (36)], BlaB (37), IMP-1 [PDB ID codes 4C1G and 4C1F
(36)], NDM-1 (38) and VIM-2 [PDB ID codes 4C1D and 4C1E
(36)]), B2 [CphA (35)] and B3 [L1 (39)] MBLs. Hence we com-
pared the BTZ binding modes described here to those of L- and
D-captopril, which, like BTZs, feature a carboxylate group attached
to a ring system and a free thiol group, but lack the bicyclic or-
ganization and bridgehead nitrogen of the BTZ scaffold. Similar
to BTZ complexes, the free thiol of D- or L-captopril bridges the
Fig. 8. Comparisons of the mode of binding be-
tween bisthizolidines and hydrolyzed antibiotics.
Superpositions of (A) IMP-1:1a (orange; zinc ions,
light gray) with NDM-1:hydrolyzed ampicillin (PDB
ID code 3Q6X, green; zinc ions, dark gray); (B) L1:1a
(blue; zinc ions, light gray) with L1:moxalactam (PDB
2AIO, green; zinc ions, dark gray); (C) L1:1b (gray;
zinc ions, light gray) with L1:moxalactam (as in B);
(D) Sfh-I:1a (gray; zinc ions, light gray) with CphA:bia-
penem (PDB ID code 1X8I, green; zinc ions, dark gray).
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active-site zinc ions of both B1 (IMP-1 and BcII) and B3 (L1)
MBLs (Fig. S10 A–E), whereas the carboxylate interacts with K224
(B1), S223 (B3), or R228 (B1 VIM-2). However, D-captopril
binding to L1 does not involve Y32, as in the L1:1b structure
(Fig. S10D), and unlike 1b binding to BcII and IMP-1 (Fig. S10 B
and C), D-captopril binding to these targets does not feature
Zn2–nitrogen or Zn2–carboxylate interactions.
Some other thiol-based inhibitors, such as the thioenolate
ML302F (30), or mercaptoacetic acids (40), have been noted to
make additional interactions with Zn2 through their carboxylate
groups. Resemblance of D-captopril and BTZ binding is most
apparent for the B2 enzymes, where D-captopril binds to the
active site of CphA through interaction of its carboxylate group
with the zinc ion (35), as observed in the Sfh-I:1a structure (Fig.
S10F). However, thiol-binding to the Zn2 site of B2 enzymes is
possible, as observed previously in a CphA:inhibitor cocrystal
structure (PDB ID code 3IOF) (41). These data may indicate
that, when both a thiol and carboxylate are present, the car-
boxylate–Zn2 interaction may be preferable, possibly as a result
of the ability of the carboxylate group to make ancillary inter-
actions with the protein main chain.
A major hurdle in the development of small molecules as effective
countermeasures for infections by opportunistic Gram-negative
bacteria is the requirement to penetrate the outer envelope of
the bacterial cell. Many Enterobacteriaceae, and in addition
nonfermenting species such as A. baumannii or P. aeruginosa,
have limited permeability toward many small molecule solutes.
In a previous investigation we established that BTZs can pen-
etrate Gram-negative bacteria that express the NDM-1 MBL
(17). The present work extends these results significantly by
demonstrating BTZ inhibition (as evidenced by potentiation of
carbapenem antimicrobial activity) of MBL activity for enzymes
of all three subclasses expressed in E. coli. However, to in-
vestigate the ability of BTZs to penetrate more challenging
organisms, we also assessed MBL inhibition in clinical
S. maltophilia isolates. S. maltophilia is a versatile opportunist
pathogen of compromised patients (42), and is attracting in-
creasing attention as a pathogen of note in the biology of cystic
fibrosis lung disease, with chronic infection identified as a risk
factor for pulmonary exacerbations (43). S. maltophilia is a
notoriously resistant organism with increased efflux pump ac-
tivity, porin reduction, and two inducible β-lactamases (L1 and
L2), that collectively confer resistance to most β-lactams (29).
Ticarcillin–clavulanate is a combination shown to be effective
against some S. maltophilia infections (44), but may be com-
promised by β-lactamase production (45). Therefore, the ability
of BTZs to restore β-lactam efficacy against a nosocomial
S. maltophilia isolate indicates potential effectiveness in clini-
cally relevant situations, where cross-class inhibition must extend
to extensively drug-resistant physiological strains.
Fig. 9. 1b binding to B1 MBLs IMP-1 and BcII closely resembles binding of hydrolyzed antibiotic. Superpositions of NDM-1:ampicillin (green) with (A) IMP:1b and
(B) BcII:1b (gray; zinc ions, light gray). The modes of binding and ligand-protein/zinc interaction distances are shown in schematic representation for (C) NDM-1:
hydrolyzed ampicillin, (D) IMP-1:1b, and (E) BcII:1b.
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In closing, we report BTZs achieve cross-class MBL inhibition
despite the structural diversity and zinc requirements of the
different enzyme targets. The ability of the unique BTZ scaffold
to bind in multiple orientations is likely a result of the substrate-
like design that is decorated with two strong metal-binding groups
(-SH and -COOH). Indeed, the multiple binding modes possible
for B1 and B3 enzymes accord with the broad substrate spectrum
of these enzymes, whereas the B2 MBL, which shows preference
for carbapenem substrates, shows some stereochemical preference.
BTZs therefore provide a novel, efficient strategy for cross-class
MBL inhibition, show activity against target bacterial pathogens as
well as in vitro, and thus justify efforts at further improvement to
enhance potency and clinical applicability.
Materials and Methods
Synthesis of Bisthiazolidines. 1a (L-CS319; (2R,5S,8R)-8-carboxylate-2-
mercaptomethyl-1-aza-3,6-dithiobicyclo[3.3.0] octane); 1b (D-CS319; (2S,5R,8S)-
8-carboxylate-2-mercaptomethyl-1-aza-3,6-dithiobicyclo[3.3.0] octane); 2a (L-VC26;
(2R,5S,8R)-2-mercaptomethyl-7-dimethyl-8-carboxylate-1-aza-3,6-dithiobicy-
clo[3.3.0] octane); and 2b (D-VC26; (2S,5R,8S)-2-mercaptomethyl-7-dimethyl-8-
carboxylate-1-aza-3,6-dithiobicyclo[3.3.0] octane) were synthesized as previously
described (18). The L- and D- notation thus refers to the 2R,5S,8R and 2S,5R,8S
chiralities of the BTZs, respectively.
Purification of Soluble MBLs. IMP-1, L1, and Sfh-I lacking the first 21 amino
acids were cloned into pOPINF vectors (46) resulting in a N-terminally His6-
tagged protein cleavable with 3C protease. BcII was cloned into the pET28a
vector (Novagen) using NdeI and SalI restriction sites, resulting in a N-ter-
minally His6-tagged protein cleavable with thrombin. For IMP-1, L1, and Sfh-I
production, E. coli SoluBL21 (DE3) cells (Genlantis) bearing pOPINF were
grown at 37 °C in auto-induction terrific broth media (Formedium) for 8 h,
then left overnight at 20 °C. BcII was overexpressed in E. coli BL21(DE3),
grown at 37 °C in LB medium to A600 0.6, when 0.5 mM IPTG and 0.5 mM
ZnSO4 were added (16 h, 18 °C). Cells were harvested by centrifugation
(6,500 × g, 10 min).
For L1, cells were resuspended in 50 mM Hepes pH 8.0, 400 mM NaCl,
Complete EDTA-free protease inhibitor mixture (Roche), 10 μM ZnCl2, and
broken by two passages through a cell disruptor (30,000 psi). After centri-
fugation (100,000 × g, 1 h), supernatant (plus 8 mM imidazole) was in-
cubated 2 h with Ni-NTA resin (Qiagen); 1 mM β-mercaptoethanol was
included in all subsequent buffers. Protein-bound resin was washed in Buffer
A (50 mM Tris pH 7.5, 400 mM NaCl, 10 μM ZnCl2) plus 10 mM imidazole,
then with the same buffer plus 0.1% Triton X-100. Resin was further washed
in Buffer A plus 20 mM imidazole and protein eluted in 50 mM Tris pH 7.5,
200 mM NaCl, 10 μM ZnCl2, 400 mM imidazole. Imidazole was reduced to
10 mM in an Amicon 10-kDa centrifugal filter. The tag was removed by 3C
protease cleavage (4 °C, overnight) and capture on Ni-NTA resin. L1 was
subsequently loaded onto a Superdex S200 column equilibrated in 10 mM
Tris pH 7.0, 100 mM NaCl, 100 μM ZnSO4. Peak fractions were concentrated
to 23 mg/mL. For crystallization, L1 protein was supplemented with 5 mM
ZnSO4. IMP-1 was purified similar to L1, except 1 mM TCEP (rather than
β-mercaptoethanol) was included in all buffers, and protein loaded onto a
Superdex S75 column equilibrated in 50 mM Tris pH 7.5, 150 mM NaCl,
100 μM ZnCl2, 1 mM TCEP, and concentrated to 25 mg/mL Sfh-I was purified as
L1, except protein was loaded on to a Superdex S75 column equilibrated in
50 mM Hepes pH 7.0 and concentrated to 15 mg/mL. For BcII, cells were
resuspended in Buffer B (50 mM Tris pH 8.0, 200 mM NaCl) supplemented
with 10 μg/mL DNase, 4 mMMgCl2, and 2 mM phenylmethylsulfonyl fluoride
and disrupted by sonication. After centrifugation (60 min, 15,000 × g) and
supernatant loaded on to Ni-Sepharose resin equilibrated with Buffer A. The
column was washed with 100 mL of Buffer B and BcII was eluted with Buffer
B plus 500mM imidazole using a linear gradient (0–100% Buffer B, over 100mL).
The his-tag was removed with thrombin and capture on Ni-Sepharose resin.
Flow-through (cleaved BcII) was diluted (1:5) in Buffer C (100 mMHepes pH 7.0,
1 mM ZnSO4) and loaded on to CM-Sepharose resin equilibrated with Buffer C.
The column was washed with 100 mL of Buffer C and BcII was eluted with
Buffer C plus 400 mM NaCl, with a purity >95%, as determined by SDS/PAGE.
Protein was concentrated to 15 mg/mL using Centricon ultrafiltration devices
(Millipore) and exchanged into 10 mM Tris·HCl pH 7, 50 mM NaCl, 1 mM DTT,
and 1 mM ZnSO4.
GOB-18 was purified cytoplasmically, and reconstituted in its fully active
monozinc form, as previously described (27).
Enzyme Assays. Inhibition constants (Ki) were determined by following imi-
penem hydrolysis at 300-nm absorbance (JascoV-670 spectrophotometer) in
Buffer C (10 mM Hepes pH 7.5, 0.2 M NaCl, 50 μg/mL BSA; B1 and B3 en-
zymes) or Buffer C plus 20 μM ZnSO4 (B2 Sfh-I). BTZs were dissolved in DMSO
(30 mM) and diluted in reaction buffer to the desired concentration. The
presence of 1% DMSO did not alter the enzyme activity. Assays were initi-
ated by enzyme addition to the substrate and inhibitor mixture. Kis were
determined by data fitting to the Competitive Inhibition Model imple-
mented in GraphPad Prism 5.0.
In Vitro Time-Kill Study. E. coli DH5α carrying the pMBLe plasmid (17)
expressing MBLs BcII, IMP-1, Sfh-I, and GOB-18 were cultured overnight at
37 °C in Mueller Hinton Broth (MHB) supplemented with 25 mg/L genta-
mycin. Next, 1.5 μL of the overnight cultures were inoculated in 1 mL MHB
supplemented with 100 μM isfopropyl-β-D-thiogalactopyranoside (IPTG) to
obtain a bacterial suspension of ∼106 CFU/mL To examine the effects of the
novel BTZs compounds on bacterial growth, bacterial suspensions were
grown at 37 °C under different conditions: MHB alone (growth control) or
supplemented with 0.4% DMSO (growth control), sublethal imipenem
concentrations, 100 mg/L of each inhibitor, or a combination of imipenem
and inhibitor. Samples (10 μL) were removed at intervals of 100, 300, and
500 min of exposure, and serial dilutions performed on MHB. Viable cell
numbers were determined by spotting 20 μL of each dilution on Muller Hinton
Agar (MHA). Plates were incubated (37 °C overnight), and colonies counted.
Results are the mean of three biological replicates. Assays using a clinical
isolate of S. maltophilia (strain C1: L1 and L2 producer) were performed sim-
ilarly except samples were taken after 4, 8, and 12 h of treatment.
Crystallization and Structure Determination. L1 and Sfh-I were crystallized as
previously described (14, 15). IMP-1 was crystallized using sitting-drop vapor
diffusion in CrysChem24 well plates (Hampton Research) at 18 °C. Drops
were formed by mixing 1-μL protein solution with 1-μL crystallization re-
agent [0.1 M sodium cacodylate pH 6.0, 0.2 M sodium acetate, 25% (wt/vol)
PEG8000] and equilibrated against 500 μL. Crystals grew to maximum size in
7 d. BcII was crystallized using hanging-drop vapor diffusion in 24-well plates
(Hampton Research) at 20 °C. Drops were formed by mixing 1-μL protein
solution with 1-μL crystallization reagent [180 mM K2SO4, 20% (wt/vol) PEG
3350, 1 mM DTT, and 1 mM ZnSO4] and equilibrated against 1 mL. Crystals
grew to maximum size within 3–5 d.
Inhibitor bound complexes were obtained by soaking crystals for 15–60 min
in 2- to 5-mM inhibitor dissolved in cryoprotectant [L1: 0.05 M Hepes pH 7.5,
1.75 M (NH4)2SO4, 1.25% (vol/vol) PEG400, 25% (vol/vol) glycerol, 2 mM TCEP;
IMP-1: 0.1 M sodium cacodylate, 0.15M sodium acetate, 25% (vol/vol) ethylene
glycol, 15% (wt/vol) PEG8000, 2 mM TCEP, 50 μM ZnCl2; Sfh-I: 0.02 M Hepes
pH7.5, 0.12 M sodium acetate, 14% (wt/vol) PEG3350, 20% (vol/vol) glycerol,
2 mM TCEP; BcII: reservoir plus 20% (vol/vol) glycerol]. IMP-1 native crystals
were cryoprotected by soaking (1 min) in IMP-1 cryoprotectant. Crystals were
looped and flash-frozen in liquid nitrogen. Diffraction data were collected at
100K on beamlines I02, I03, I04, I04-1, or I24 (Diamond Light Source, United
Kingdom) or on a high-flux Rigaku RAXIS IV++ in-house X-ray generator (BcII,
Los Alamos National Laboratory). Datasets were indexed and integrated using
XDS (47), iMosflm (48), or HKL2000 (49) and scaled using Aimless in CCP4 (50)
or HKL2000 (49). Crystals were not prone to radiation damage in all cases and
relatively high Rmerge values, compared with high I/σI values, are a result of the
high redundancy of the data, or in the case of BcII:1b because of the collection
of data on a home source. Structures were phased by molecular replacement
with Phaser (51) using as starting models PDB ID codes 3I13 (52) (BcII), 1SML
(15) (L1), 1DD6 (10) (IMP-1), or 3SD9 (14) (Sfh-I). Structures were completed by
iterative rounds of manual model building in Coot (53) and refinement in
Phenix (54) or Refmac5 (55). Sfh-I crystals were pseudomerohedrally twinned
[twin law h,-k,-l, determined by Xtriage (54)], so the Sfh-I model was com-
pleted with twin refinement in Refmac5. Omit maps were calculated from the
final model after removal of the ligand and refinement in Phenix (L1, IMP-1,
BcII) or Refmac (Sfh-I). Ligand structures and geometric restraints were calcu-
lated with PRODRG (56) or Phenix eLBOW (57). Structure validation was assisted
by Molprobity (58), SFCHECK (59), and Phenix. Figures were prepared using
PyMol (60). The rmsds were calculated over Cα atoms aligned using PDBeFold
(61). Ligand buried surface areas were calculated using PDBePisa (62).
See SI Results and Fig. S11 for a discussion of the movement of the
uncomplexed di-zinc IMP-1 L3 loop between chains in the asymmetric unit.
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